Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 29; no. 11; p. 871
• Main Authors: Hui, Rui, Zhang, Min, Hao, Xiao-Meng, Zhang, Jin
• Format: Journal Article
• Language: Chinese
• Published: China 01.11.2007
• Subjects: Adult; Alanine Transaminase - blood; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Aspartate Aminotransferases - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - surgery; Carcinoma, Lobular - drug therapy; Carcinoma, Lobular - surgery; Chemotherapy, Adjuvant; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Epirubicin - administration & dosage; Epirubicin - adverse effects; Epirubicin - therapeutic use; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Follow-Up Studies; Humans; Leukopenia - chemically induced; Middle Aged; Neutropenia - chemically induced; Vomiting - chemically induced
• ISSN: 0253-3766

To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer. From March 2005 to October 2006, 98 patients with stage I - III a breast cancer were randomly assigned to receive postoperative chemotherapy with CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48) or CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50). Blood routine test were done every cycle, liver and kindey function were examined and adverse effects were recorded after every cycle. No difference of average leucocyte or neutrophil count (P >0.05) was observed in every cycle. Adverse effects of digestive tract and damage of liver function in CEF-100 group were more severe than that in CEF-60 group (P <0.05), but all adverse effects could be relieved by treatment. No severe non-hematological toxicity and cardiac toxicity in both groups were observed (P <0.05). There was no death caused by chemotherapy. Our data shows that high dose epirubicin-containin